Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?

Executive Summary

Sun Pharma’s executive vice president, biologics and dermatology, Jesper Ostergaard Jensen, elaborates on some aspects of the recent encouraging data around the company’s late stage psoriasis asset, tildrakizumab. Jensen also tells Scrip that the firm is upbeat about its acne and photodynamic therapy products in the US.

You may also be interested in...



Big Launch Year Coming Up In US For Sun But Spends High Too

Sun Pharma, India's top-ranked drug firm, has three key specialty launches lined up in the US in FY19. Management commentary was generally upbeat about the potential prospects of the three products, but also emphasized that the commercialization plans will entail significant costs.

Sun Plunges To Quarterly Loss, Outlook Challenging

Sun Pharma, India’s biggest drug firm, slid into the red in the first quarter, hit by a hefty legal payout, regulatory woes and a dramatic drop in US sales, and company founder Dilip Shanghvi said while he expected a “gradual improvement” in performance, the outlook remained challenging.

Keeping Track: Immunology In Focus As US FDA Approves Kevzara, New Breakthrough Actemra Use; J&J, Sun Advance Psoriasis Candidates

The latest immunology drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel